Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Innate Pharma SA ( (FR:IPH) ) is now available.
Innate Pharma SA announced its full-year 2024 financial results and provided a business update, highlighting significant advancements in its clinical programs. The FDA granted Breakthrough Therapy Designation to lacutamab for Sézary syndrome, underscoring its potential impact on treatment options. The company also dosed the first patient in a Phase 1 study for IPH4502, targeting advanced solid tumors, and continues to progress with IPH6501 in B-cell non-Hodgkin’s lymphoma. With a cash position of €91.1 million, Innate Pharma has extended its financial runway to mid-2026, reinforcing its commitment to delivering innovative therapies.
More about Innate Pharma SA
Innate Pharma SA is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company specializes in antibody-based NK cell engager therapeutics and antibody-drug conjugates, with a strong emphasis on advancing its proprietary ANKET® platform and ADC programs.
Technical Sentiment Signal: Hold
Current Market Cap: $167.6M
For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.